

J.P.Morgan

Q2 2025 Medtech Licensing and Venture Report

July 2025

Fueled by

DEALFORMA 



Executive summary

Strategic Consolidation: Larger deals shape medtech investment and licensing in early 2025

In Q2 2025, medtech venture investment activity continued to reflect a flight to quality, with capital concentrating in larger, later-stage rounds. Although total quarterly venture funding was lower than in Q1, investor interest remains strong for well-positioned platforms with clear clinical and commercial potential. Medtech licensing and R&D partnerships gained significant traction, with three disclosed R&D licensing deals surpassing the \$100 million upfront threshold—matching the full-year 2024 figure within just the first half of this year. M&A and IPO activity moderated in Q2, reflecting broader market caution, but investor interest in category-defining assets remains intact. With macro uncertainty and rate pressure still affecting transaction velocity, a clearer market backdrop could unlock renewed deal momentum in the quarters ahead. Here are a few highlights from our Q2 2025 report:

- **Medtech venture activity:** There were 90 venture rounds totaling \$2.6 billion in Q2 2025, bringing the H1 2025 total to \$6.8 billion across 194 rounds.
- **Medtech licensing partnerships:** In Q2 2025, 286 medtech deals were announced, disclosing a total deal value of \$4.5 billion, with over \$307 million in upfront payments. The H1 2025 total reached \$6.0 billion, with \$827 million committed upfront.
- **M&A:** 43 medtech M&A deals were announced in Q2 2025, totaling \$2.1 billion.
- **IPOs:** One medtech IPO raised \$494 million on NASDAQ, bringing the H1 2025 IPO volume to \$1 billion across three offerings.

J.P. Morgan is committed to your success. Our relationships, our capital, and our skilled team of bankers and specialists dedicated to the life sciences and healthcare sectors reflect our conviction in the pivotal contributions these clients add to their stakeholders—society, shareholders and employees alike.

Our bankers' expertise ranges from advising companies at the earliest stage of formation to the most graduated, complex M&A and capital markets transactions. Regardless of the size or stage of your company, we are prepared, equipped and enthusiastic about advising and enabling you to meet your strategic, financial and technical objectives.

Thank you for taking the time to read this report. We look forward to supporting you.

Kathryn McDonough
Head of Life Sciences
Innovation Economy, Commercial Banking
J.P. Morgan

Parameters

Medtech companies are defined as firms developing medical devices, diagnostics, therapeutic digital health and commercial research tools. Healthcare IT and payer/provider software are excluded.

Therapy areas, development stages, modalities and deal structures are segmented per the DealForma database.


Financials are based on disclosed figures curated by DealForma. Multiple tranches of the same Series are counted as one together.

Deals are tracked globally unless otherwise noted.


Data as of June 30, 2025

Medtech venture funding holds strong through first half of 2025, reaching nearly \$7B

QUARTERLY MEDTECH VENTURE INVESTMENT VS. ANNUAL VENTURE DEAL COUNT¹



10-YEAR U.S. TREASURY YIELD VS. MEDTECH VENTURE DEPLOYMENT (INDEXED)^{1,2}




The medtech venture landscape continues to show resilience, with total venture funding reaching \$6.8 billion in the first half of 2025, positioning the sector to potentially exceed 2024's \$12.7 billion full-year total. This strength was largely anchored by a standout Q1, which represented the most active quarter since early 2022.

While macroeconomic conditions, such as elevated rates, have created a more selective fundraising environment, medtech continues to attract meaningful interest from venture investors. The nearly \$7 billion raised in the first half of 2025 reflects strong conviction in startups building essential healthcare solutions. For founders, this signals that capital will still be available, particularly for those who can demonstrate both the technical rigor and commercial readiness needed to lead the next wave of healthcare innovation.


Notes: ¹Financials based on disclosed figures. Data through June 30, 2025. ²Medtech venture capital deployment is indexed to Q1 2020, where Q1 2020 = 100.

\$100M+ deals drive momentum in H1 2025

COUNT OF VENTURE INVESTMENT ROUNDS BY ROUND SIZE¹



COUNT OF R&D LICENSES BY DISCLOSED UPFRONT CASH AMOUNT¹




Q2 2025 has continued the trend of outsized rounds driving momentum within the medtech venture landscape. Of the 194 medtech venture rounds closed so far this year, 18 exceeded \$100 million, and an additional 14 surpassed \$50 million. Among the largest medtech venture rounds in Q2 2025 were the Neuralink Series E at \$650 million and the \$100MM Series C for Biolinq.

Medtech partnership and licensing upfront payments also increased, with more deals disclosing upfront payments exceeding \$100 million in Q2 2025. Three of the 17 disclosed R&D licensing deals have crossed the \$100 million threshold—matching the full-year 2024 figure within just the first half of this year. This might indicate a growing urgency among strategic partners to secure external innovation.

Note: ¹Financials based on disclosed figures. Data through June 30, 2025.

Later-stage venture rounds outpace earlier-stage nearly five-to-one in H1 2025

MEDTECH SEED AND SERIES A VENTURE ACTIVITY VS. SERIES B+ VENTURE ACTIVITY¹




Note: ¹Financials based on disclosed figures. Data through June 30, 2025.

In H1 2025, Series B+ rounds accounted for \$5.6 billion across 124 rounds—more than five times the capital deployed into Seed and Series A rounds during the same period. Seed and Series A rounds saw \$1.1 billion invested across 70 deals in H1 2025. Out of the top 10 Series A financings, five were headquartered outside of the U.S. While early-stage rounds still play an important role in the medtech venture ecosystem, their relative slowdown may signal a market that is weary of entrenched first-movers. This likely stems from a combination of various factors, such as macro uncertainty and tighter fundraising conditions. Still, the outlook remains encouraging. For early-stage founders, today's market environment rewards those who can show traction with a differentiated technology. Meanwhile, later-stage founders are well positioned to scale with conviction as capital pools remain available.

Medtech licensing captures over \$800M in upfront payments in the first half of 2025

MEDTECH R&D PARTNERSHIP, LICENSING AND CONTRACTING DEAL VALUE TOTALS AND UPFRONT CASH AS A PROPORTION OF DEAL VALUE¹




Note: ¹Financials based on disclosed figures. Data through June 30, 2025.

In the first half of 2025, medtech licensing deals reached \$6 billion in total announced deal value—with \$827 million paid upfront. That represents 14% of total deal value, the second-highest upfront share in nearly a decade. This rise in upfront payments likely reflects stronger convictions from strategic partners who are increasingly willing to pay upfront for access to high-potential technologies that drive savings to a variety of stakeholders.


Notable deals include: The joint venture between Hogen AI and MeiraGTx, which, with \$230 million upfront, aims to apply Hogen's multimodal generative foundation models to obesity; and the Viking Therapeutics' agreement with CordenPharma, which features \$150 million upfront for autoinjectors and formulations of Viking's drug.

Medtech M&A activity slows in Q2 2025, but future market stability could bring back appetite


MEDTECH M&A ACTIVITY^{1,2}



MEDIAN M&A UPFRONT CASH AND EQUITY^{1,2}



COUNT OF M&A DEALS BY ACQUIRED COMPANY TYPE^{1,2}




Note: ¹Financials based on disclosed figures. Data through June 30, 2025. ²Medtech M&A with any buyer type, acquisition options, and reverse mergers.

Medtech M&A activity slowed in Q2 2025, with 43 transactions totaling \$2.1 billion—down from the 55 deals and \$9.2 billion recorded in Q1. Median upfront payments also fell to \$54 million, suggesting a more cautious tone from acquirers. This deceleration reflects the broader macro environment, where ongoing uncertainty, elevated rates and valuation mismatches have made dealmaking more selective.

Still, many strategic acquirers continue to signal strong interest in expanding capabilities across medical devices, diagnostics, therapeutic digital health and commercial research tools. A notable Q2 2025 medtech acquisition was Merit Medical's acquisition of Biolife Delaware, a manufacturer of hemostatic devices.

H1 2025 medtech IPO dollars surpass full-year 2024

NASDAQ AND NYSE COMPLETED IPOS IN MEDTECH: TOTALS (\$B) AND COUNT^{1,2}



Note: ¹Financials based on disclosed figures. Data through June 30, 2025. ²Includes only IPOs \$15 million and larger by completion date.

Chase, J.P. Morgan, JPMorgan, JPMorgan Chase, and Story by J.P. Morgan are marketing names for certain businesses of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide (collectively, "JPMC", "We", "Our" or "Us", as the context may require). The information in this content (website, article, event invitation or other form) does not represent an offer or commitment to provide any product or service. The views, opinions, analyses, estimates and strategies, as the case may be ("views"), expressed in this content are those of the respective authors and speakers named in those pieces, and/or the JPMC departments that publish the content and may differ from those of JPMorgan Chase Commercial Banking and/or other JPMC employees and affiliates. These views are as of a certain date and often based on current market conditions, and are subject to change without notice. Any examples used are generic, hypothetical and for illustration purposes only. Any prices/quotes/statistics included have been obtained from sources deemed to be reliable, but we do not guarantee their accuracy or completeness. To the extent indices have been used in this content, please note that it is not possible to invest directly in an index. This is not a product of the Research Department of J.P. Morgan Securities LLC. This information in no way constitutes research and should not be treated as such. Any information related to cybersecurity provided is intended to help clients protect themselves from cyber fraud, not to provide a comprehensive list of all types of cyber fraud activities nor to identify all types of cybersecurity best practices.

Copying, re-publishing, or using this material or any of its contents for any other purpose is strictly prohibited without prior written consent from JPMorgan. In preparing this material, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information that was acquired from public sources. Any mentions of third-party trademarks, brand names, products and services are for referential purposes only and any mention thereof is not meant to imply any sponsorship, endorsement, or affiliation unless otherwise noted. Notwithstanding anything to the contrary, the statements in this material are not intended to be legally binding. Any products, services, terms or other matters described herein (other than in respect of confidentiality) are subject to, and superseded by, the terms of separate legally binding documentation and/or are subject to change without notice.

The information in this content is not advice on legal, tax, investment, accounting, regulatory, technology or other matters. You should always consult your own financial, legal, tax, accounting or similar advisors before making any financial or investment decisions, or entering into any agreement for JPMC products or services. In no event shall JPMC or any of its directors, officers, employees or agents be liable for any use of, for any decision made or action taken in reliance upon, or for any inaccuracies or errors in or omissions from, the information in this content. We are not acting as your or any client's agent, fiduciary or advisor, including, without limitation, as a Municipal Advisor under the Securities and Exchange Act of 1934. JPMC assumes no responsibility or liability whatsoever to you or any client with respect to such matters, and nothing herein shall amend or override the terms and conditions in the agreement(s) between JPMC and any client or other person.

The information in this content does not include all applicable terms or issues, and is not intended as an offer or solicitation for the purchase or sale of any product or service. Our products and services are subject to applicable laws and regulations, as well as our service terms and policies. Not all products and services are available in all geographic areas or to all customers. In addition, eligibility for particular products and services will be determined by JPMC, including satisfaction of applicable legal, tax, risk, credit and other due diligence, and JPMC's "know your customer", anti-money laundering, anti-terrorism and other policies and procedures. Credit is subject to approval. Rates and programs are subject to change. Certain restrictions apply.

Products and services may be provided by banking affiliates, securities affiliates or other JPMC affiliates or entities. In particular, securities brokerage services other than those that can be provided by banking affiliates will be provided by appropriate registered broker/dealer affiliates, including J.P. Morgan Securities LLC and J.P. Morgan Institutional Investments Inc. Any securities provided or otherwise administered by such brokerage services are not deposits or other obligations of, and are not guaranteed by, any banking affiliate and are not insured by the Federal Deposit Insurance Corporation. Certain financial products and services are required by law to be provided only by licensed representatives and affiliates. Inquiries regarding such products and services will be referred to a licensed representative or a licensed affiliate. The information in this content is not an offer to sell, or solicit an offer to purchase, any securities by anyone in any jurisdiction in which such offer or solicitation is not authorized, or in which JPMC or the person making such an offer is not qualified to do so, or to anyone to whom it is unlawful to make such an offer or solicitation, or to anyone in any jurisdiction outside of the United States. Nothing in this content constitutes any commitment by JPMC to underwrite, subscribe for or place any securities, or to extend or arrange credit, or to provide any other product or service. JPMC contact persons may be employees or officers of any JPMC subsidiary or affiliate.

Any information requested on this invitation, page or other relevant registration form will be processed for the purposes of preparation and administration of this event. Providing the requested information will also assist us in ensuring that the event is properly tailored to meet the requirements of the attendees. By providing the information requested, you are consenting to your data being processed by employees and agents of JPMC as well as potential co-organizers for these purposes. You expressly consent to our use of your information in the manner described herein and in our privacy policy (www.jpmorgan.com/privacy).

Please note that any JPMC-hosted event or webinar that you register to attend may be recorded, and videos, photographs and other recordings may be taken, where you may be captured participating in the event. By providing the information requested on the registration form, you consent to the publication of such photographs, videos, recordings and/or likenesses (whether edited, adapted, modified or copied), and their use by us and those that we authorize, without prior notice or compensation, in any way which we may see fit now or in the future, including but not limited to, marketing and advertising. Further, you release JPMC and its employees and agents from all claims of every kind on account of such use. You also acknowledge and agree that the replay links, if any, will be shared with JPMC clients and prospects who were invited but did not register/attend, and also potentially to other third parties if the topics are relevant to them. If you do not agree with any statements in this paragraph, please make a member of our staff aware on the day of the event.

The statements made in this content or during this event, or provided in materials as part of this event, are proprietary to JPMC and are not intended to be legally binding. Any products and services described during these events are offered by JPMC subject to applicable laws and regulations and service terms.

We will provide reasonable accessibility accommodations brought to our attention.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: <https://www.jpmorgan.com/IBOR>.

© 2025 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A., organized under the laws of the U.S.A. with limited liability. Deposits held in non-U.S. branches, are not FDIC insured.